ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its ...
(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the pricing of its previously announced underwritten public ...
Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva's organizational build-out as it advances toward potential commercialization.Axel-Sven Malkomes ...
Eater Boston on MSN
Boston’s best steakhouses
Where to eat steaks, chops, and creamed spinach around town ...
D&D Pharmatech, a company specializing in the development of GLP-1 (glucagon-like peptide-1) class novel drugs, announced on April 22 that it has ...
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting ...
Actively planning for HU6’s late-stage development in MASH - - HU6 is potential best-in-class oral MASH therapy designed to address unmet needs in MASH through a unique energy expenditure approach - ...
SIOUX FALLS, S.D. (Dakota News Now) - Downtown Sioux Falls announced the three winners for Mash Madness 2026 on Tuesday! This year’s Mash Madness gained 2,781 votes, a 15% increase from 2025, and ...
Welcome to Taste Test, where every week our critic Jonah Flicker explores the most buzzworthy and interesting whiskeys in the world. Check back each Sunday for his latest whiskey review. Just because ...
NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results